|
サイトウ カヨコ
Saito Kayoko
齋藤 加代子 所属 医学部 医学科（東京女子医科大学病院） 職種 特任教授 |
|
| 論文種別 | 原著 |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | Life-Saving Treatments for Spinal Muscular Atrophy: Global Access and Availability. |
| 掲載誌名 | 正式名：Neurology. Clinical practice 略 称：Neurol Clin Pract ISSNコード：21630402/21630402 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 14(1),pp.e200224 |
| 国際共著 | 国際共著 |
| 著者・共著者 | Armengol Victor D, Darras Basil T, Abulaban Ahmad A, Alshehri Ali, Barisic Nina, Ben-Omran Tawfeg, Bernert Guenther, Castiglioni Claudia, Chien Yin-Hsiu, Farrar Michelle A, Kandawasvika Gwendoline, Khadilkar Satish, Mah Jean, Marini-Bettolo Chiara, Osredkar Damjan, Pfeffer Gerald, Piazzon Flavia B, Pitarch Castellano Inmaculada, Quijano-Roy Susana, Saito Kayoko, Shin Jin-Hong, Vázquez-Costa Juan F, Walter Maggie C, Wanigasinghe Jithangi, Xiong Hui, Griggs Robert C, Roy Bhaskar |
| 発行年月 | 2024/02 |
| 概要 | BACKGROUND AND OBJECTIVES:Spinal muscular atrophy (SMA) is a neurodegenerative disorder manifesting with progressive muscle weakness and atrophy. SMA type 1 used to be fatal within the first 2 years of life, but is now treatable with therapies targeting splicing modification and gene replacement. Nusinersen, risdiplam, and onasemnogene abeparvovec-xioi improve survival, motor strength, endurance, and ability to thrive, allowing many patients to potentially attain a normal life; all have been recently approved by major regulatory agencies. Although these therapies have revolutionized the world of SMA, they are associated with a high economic burden, and access to these therapies is limited in some countries. The primary objective of this study was to compare the availability and implementation of treatment of SMA from different regions of the world.METHODS:In this qualitative study, we surveyed health care providers from 21 countries regarding their experiences caring for patients with SMA. The main outcome measures were provider survey responses on newborn screening, drug availability/access, barriers to treatment, and related questions.RESULTS:Twenty-four providers from 21 countries with decades of experience (mean 26 years) in treating patients with SMA responded to the survey. Nusinersen was the most available therapy for SMA. Our survey showed that while genetic testing is usually available, newborn screening is still unavailable in many countries. The provider-reported treatment cost also varied between countries, and economic burden was a major barrier in treating patients with SMA.DISCUSSION:Overall, this survey highlights the global inequality in managing patients with SMA. The spread of newborn screening is essential in ensuring improved access to care for patients with SMA. With the advancement of neurotherapeutics, more genetic diseases will soon be treatable, and addressing the global inequality in clinical care will require novel approaches to mitigate |
| DOI | 10.1212/CPJ.0000000000200224 |
| PMID | 38107546 |